PEPTONIC medical (publ) progress towards next clinical study

PEPTONIC medical (publ) today announced it has engaged five study sites, all of them in Sweden, to participate in the next Phase 2b study and appointed A+ Science AB as the CRO to coordinate and monitor the study with PEPTONIC’s developmental estrogen-free product Vagitocin® in post-menopausal women. The enrollment of the first patient is due […]

VD-intervju publicerad i samband med första handelsdag på Aktietorget

Idag noteras PEPTONIC Medical på AktieTorget och i samband med det har VD, Dan Markusson, intervjuats av Redeye. Titta på intervjun » Aktiens handelsbeteckning är PMED. Aktiens ISIN-kod är SE0005962206. För ytterligare information om PEPTONIC medical AB (publ), vänligen kontakta: Dan Markusson, VD Telefon: 08-530 20 110 E-post: PEPTONIC medical AB (publ) är ett […]

PEPTONIC noteras på AktieTorget den 2 juli 2014

Peptonic har genomfört en riktad nyemission samt en spridningsemission under maj respektive juni månad som tillsammans tillför bolaget drygt 22 mkr före emissionskostnader. Efter de två emissionerna har bolaget ca 250 aktieägare, varav ca 200 tillkom i emissionerna. Bolaget står nu redo att starta sin planerade fas IIb studie samt att notera bolaget på AktieTorget […]

Road show calendar of PEPTONIC medical

PEPTONIC medical today announced the tentative program for company presentations during the subscription period for the rights issue in connection with the planned listing (IPO) on Aktietorget Stock Exchange (Stockholm) in June. May 27th – AktieTorget Uppsala June 3rd – AktieTorget Malmö June 4th – AktieTorget Göteborg June 9th – Småbolagsdagen Stockholm June 10th – […]

Nadia Whittley joins the PEPTONIC medical Board of Directors

PEPTONIC medical today announces that, at the PEPTONIC medical Annual General Meeting on April 8th, Mrs Nadia Whittley was elected as a new member to the Board of Directors. Mrs Whittley recently assumed the position as CEO of Pharmarama Ltd. (UK) and she has a long career in the pharmaceutical and medical device industry having […]

Resolutions from the Annual General Meeting

PEPTONIC medical (publ) today announced that the Annual General Meeting (AGM) on April 8th resolved to make the Company to a public company. In conjunction with this resolution, a rights issue was carried out resulting in an increased share capital from 297,098 SEK to 594,196 SEK. The AGM also resolved in favour of the Company […]

PEPTONIC medical (publ) recruits Business Development professional

PEPTONIC medical today announced that it has recruited Johan Inborr to lead the business development activities of the company on a consultancy basis. Johan is an experienced business development executive having held similar positions in pharmaceutical and medtech companies such as Medivir, Vironova and Carmeda with a long track record in in- and out-licensing, and […]

PEPTONIC medical raises SEK 6.9 million

PEPTONIC medical today announced that it has raised SEK 6.9 million in a directed private placement to existing and new shareholders. After the private placement, the number of shareholders in the company is 53. About PEPTONIC medical PEPTONIC medical is an innovative Swedish pharmaceutical company developing oxytocin based products e.g. for the treatment of menopausal […]